Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis

Eiko Nishi, Hideto Kameda, Hiroe Ogawa, Hayato Nagasawa, Hirofumi Takei, Ayumi Okuyama, Takahiko Kurasawa, Tsuneo Kondo, Koji Nishimura, Yuichiro Shirai, Ryota Sakai, Tatsuya Ito, Tsutomu Takeuchi, Koichi Amano

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: We investigated the efficacy of a high-dose intermittent dosing treatment method (weekly mizoribine pulse therapy) conceived in the hope of achieving better efficacy by increasing the peak blood levels of mizoribine in patients with refractory lupus nephritis. Methods: Seventeen patients with lupus nephritis who had been resistant to corticosteroid and immunosuppressant therapy received weekly mizoribine pulse therapy. Mizoribine (350 mg) was administered three times at 12 h intervals over 2 consecutive days (700 mg for day 1 and 350 mg for day 2), followed by a washout period from day 3 to day 7. Results: This therapeutic strategy enabled the peak blood levels of mizoribine to be increased to more than 3 μg/mL in most of the patients. Although SLEDAI, anti-ds-DNA antibody titer, CH-50, and serum albumin level did not significantly improve, urinary protein levels decreased, and it was possible to taper the dose of concomitant steroids. Using our definition of clinical response, 10 of the 17 patients were responders and 4 of them were nonresponders. The average peak serum mizoribine concentration of the responders was as high as 3.5 μg/mL. Elevation of serum liver enzymes was seen in 1 patient, and hyperuricemia occurred in 4 cases, but none of these adverse events were serious. Conclusion: Intermittent administration of mizoribine can increase blood levels and may be effective for refractory lupus nephritis.

Original languageEnglish
Pages (from-to)97-103
Number of pages7
JournalModern Rheumatology
Volume23
Issue number1
DOIs
Publication statusPublished - 2013 Jan

Fingerprint

Lupus Nephritis
Therapeutics
Complement Hemolytic Activity Assay
Hyperuricemia
Antinuclear Antibodies
Immunosuppressive Agents
bredinin
Serum
Serum Albumin
Adrenal Cortex Hormones
Steroids
Liver
DNA
Enzymes

Keywords

  • Lupus nephritis
  • Mizoribine

ASJC Scopus subject areas

  • Rheumatology

Cite this

Nishi, E., Kameda, H., Ogawa, H., Nagasawa, H., Takei, H., Okuyama, A., ... Amano, K. (2013). Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Modern Rheumatology, 23(1), 97-103. https://doi.org/10.1007/s10165-012-0645-6

Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. / Nishi, Eiko; Kameda, Hideto; Ogawa, Hiroe; Nagasawa, Hayato; Takei, Hirofumi; Okuyama, Ayumi; Kurasawa, Takahiko; Kondo, Tsuneo; Nishimura, Koji; Shirai, Yuichiro; Sakai, Ryota; Ito, Tatsuya; Takeuchi, Tsutomu; Amano, Koichi.

In: Modern Rheumatology, Vol. 23, No. 1, 01.2013, p. 97-103.

Research output: Contribution to journalArticle

Nishi, E, Kameda, H, Ogawa, H, Nagasawa, H, Takei, H, Okuyama, A, Kurasawa, T, Kondo, T, Nishimura, K, Shirai, Y, Sakai, R, Ito, T, Takeuchi, T & Amano, K 2013, 'Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis', Modern Rheumatology, vol. 23, no. 1, pp. 97-103. https://doi.org/10.1007/s10165-012-0645-6
Nishi E, Kameda H, Ogawa H, Nagasawa H, Takei H, Okuyama A et al. Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Modern Rheumatology. 2013 Jan;23(1):97-103. https://doi.org/10.1007/s10165-012-0645-6
Nishi, Eiko ; Kameda, Hideto ; Ogawa, Hiroe ; Nagasawa, Hayato ; Takei, Hirofumi ; Okuyama, Ayumi ; Kurasawa, Takahiko ; Kondo, Tsuneo ; Nishimura, Koji ; Shirai, Yuichiro ; Sakai, Ryota ; Ito, Tatsuya ; Takeuchi, Tsutomu ; Amano, Koichi. / Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. In: Modern Rheumatology. 2013 ; Vol. 23, No. 1. pp. 97-103.
@article{10502ff1e4a7454886671e918435f591,
title = "Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis",
abstract = "Objective: We investigated the efficacy of a high-dose intermittent dosing treatment method (weekly mizoribine pulse therapy) conceived in the hope of achieving better efficacy by increasing the peak blood levels of mizoribine in patients with refractory lupus nephritis. Methods: Seventeen patients with lupus nephritis who had been resistant to corticosteroid and immunosuppressant therapy received weekly mizoribine pulse therapy. Mizoribine (350 mg) was administered three times at 12 h intervals over 2 consecutive days (700 mg for day 1 and 350 mg for day 2), followed by a washout period from day 3 to day 7. Results: This therapeutic strategy enabled the peak blood levels of mizoribine to be increased to more than 3 μg/mL in most of the patients. Although SLEDAI, anti-ds-DNA antibody titer, CH-50, and serum albumin level did not significantly improve, urinary protein levels decreased, and it was possible to taper the dose of concomitant steroids. Using our definition of clinical response, 10 of the 17 patients were responders and 4 of them were nonresponders. The average peak serum mizoribine concentration of the responders was as high as 3.5 μg/mL. Elevation of serum liver enzymes was seen in 1 patient, and hyperuricemia occurred in 4 cases, but none of these adverse events were serious. Conclusion: Intermittent administration of mizoribine can increase blood levels and may be effective for refractory lupus nephritis.",
keywords = "Lupus nephritis, Mizoribine",
author = "Eiko Nishi and Hideto Kameda and Hiroe Ogawa and Hayato Nagasawa and Hirofumi Takei and Ayumi Okuyama and Takahiko Kurasawa and Tsuneo Kondo and Koji Nishimura and Yuichiro Shirai and Ryota Sakai and Tatsuya Ito and Tsutomu Takeuchi and Koichi Amano",
year = "2013",
month = "1",
doi = "10.1007/s10165-012-0645-6",
language = "English",
volume = "23",
pages = "97--103",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis

AU - Nishi, Eiko

AU - Kameda, Hideto

AU - Ogawa, Hiroe

AU - Nagasawa, Hayato

AU - Takei, Hirofumi

AU - Okuyama, Ayumi

AU - Kurasawa, Takahiko

AU - Kondo, Tsuneo

AU - Nishimura, Koji

AU - Shirai, Yuichiro

AU - Sakai, Ryota

AU - Ito, Tatsuya

AU - Takeuchi, Tsutomu

AU - Amano, Koichi

PY - 2013/1

Y1 - 2013/1

N2 - Objective: We investigated the efficacy of a high-dose intermittent dosing treatment method (weekly mizoribine pulse therapy) conceived in the hope of achieving better efficacy by increasing the peak blood levels of mizoribine in patients with refractory lupus nephritis. Methods: Seventeen patients with lupus nephritis who had been resistant to corticosteroid and immunosuppressant therapy received weekly mizoribine pulse therapy. Mizoribine (350 mg) was administered three times at 12 h intervals over 2 consecutive days (700 mg for day 1 and 350 mg for day 2), followed by a washout period from day 3 to day 7. Results: This therapeutic strategy enabled the peak blood levels of mizoribine to be increased to more than 3 μg/mL in most of the patients. Although SLEDAI, anti-ds-DNA antibody titer, CH-50, and serum albumin level did not significantly improve, urinary protein levels decreased, and it was possible to taper the dose of concomitant steroids. Using our definition of clinical response, 10 of the 17 patients were responders and 4 of them were nonresponders. The average peak serum mizoribine concentration of the responders was as high as 3.5 μg/mL. Elevation of serum liver enzymes was seen in 1 patient, and hyperuricemia occurred in 4 cases, but none of these adverse events were serious. Conclusion: Intermittent administration of mizoribine can increase blood levels and may be effective for refractory lupus nephritis.

AB - Objective: We investigated the efficacy of a high-dose intermittent dosing treatment method (weekly mizoribine pulse therapy) conceived in the hope of achieving better efficacy by increasing the peak blood levels of mizoribine in patients with refractory lupus nephritis. Methods: Seventeen patients with lupus nephritis who had been resistant to corticosteroid and immunosuppressant therapy received weekly mizoribine pulse therapy. Mizoribine (350 mg) was administered three times at 12 h intervals over 2 consecutive days (700 mg for day 1 and 350 mg for day 2), followed by a washout period from day 3 to day 7. Results: This therapeutic strategy enabled the peak blood levels of mizoribine to be increased to more than 3 μg/mL in most of the patients. Although SLEDAI, anti-ds-DNA antibody titer, CH-50, and serum albumin level did not significantly improve, urinary protein levels decreased, and it was possible to taper the dose of concomitant steroids. Using our definition of clinical response, 10 of the 17 patients were responders and 4 of them were nonresponders. The average peak serum mizoribine concentration of the responders was as high as 3.5 μg/mL. Elevation of serum liver enzymes was seen in 1 patient, and hyperuricemia occurred in 4 cases, but none of these adverse events were serious. Conclusion: Intermittent administration of mizoribine can increase blood levels and may be effective for refractory lupus nephritis.

KW - Lupus nephritis

KW - Mizoribine

UR - http://www.scopus.com/inward/record.url?scp=84872489034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872489034&partnerID=8YFLogxK

U2 - 10.1007/s10165-012-0645-6

DO - 10.1007/s10165-012-0645-6

M3 - Article

C2 - 22526831

AN - SCOPUS:84872489034

VL - 23

SP - 97

EP - 103

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -